The personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial causing Moderna’s share price to triple overnight. The data from the phase 3 trials suggests that the Moderna and Merck combo could be a new treatment option for patients with the deadliest form of skin cancer. #News #health #science #medicine